PFE News & Events

Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 Breakwater trial, evaluating Bratovi in combination with cetuximab and Folfiri versus Folfiri with or without bevacizumab in patients with previously untreated metastatic colorectal cancer, mCRC, with a BRAF V600E mutation. These results will be presented today in a late-breaking oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in the Annals of Oncology. As previously reported, Cohort 3 met its primary endpoint of objective response rate by blinded independent central review. Results for the key secondary endpoint of progression-free survival by BICR, being presented at ASCO, show median PFS was nearly doubled with the BRAFTOVI combination regimen versus the comparator.

Pfizer announced detailed results from the Phase 3 Talapro-3 study of Talzenna, an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi, an androgen receptor pathway inhibitor, in men with homologous recombination repair gene-mutated metastatic castration-sensitive prostate cancer, mCSPC, also known as metastatic hormone-sensitive prostate cancer, mHSPC. These results will be presented in a late-breaking oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in The New England Journal of Medicine. Talzenna plus Xtandi demonstrated a 52% reduction in the risk of radiographic progression or death compared to placebo plus Xtandi. At three years, radiographic progression-free survival rates were estimated at 77% in patients treated with Talzenna plus XTANDI versus 56% in patients treated with placebo plus Xtandi. With a median follow-up of over 37 months, median rPFS was not reached in the Talzenna plus Xtandi arm and was 46 months with placebo and Xtandi.

Pfizer announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating Lorbrena versus Xalkori in people with previously untreated, anaplastic lymphoma kinase-positive advanced or metastatic non-small cell lung cancer, NSCLC. At seven years, patients treated with Lorbrena had a 55% likelihood of remaining alive without disease progression compared to 3% in the Xalkori treatment arm. Further, an updated analysis at seven years of median follow-up showed that investigator-assessed median progression-free survival, PFS, had not been reached with Lorbrena, with an estimated Hazard Ratio of 0.19, representing an 81% reduction in the risk of disease progression or death compared to Xalkori. Full results from the analysis will be presented today in an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in Annals of Oncology.